Skip to main content

Advertisement

Table 3 Characteristics of 56 patients with BRAF V600E-mutated mCRC in standard therapy group (treated with cytotoxic doublets with or without bevacizumab regimen) and intensive therapy group (treated with modified FOLFOXIRI regimen)

From: Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study

Variable Standard therapy group (n = 50) Intensive therapy group (n = 6)
Gender
 Male 16 (32.0) 4 (66.7)
 Female 34 (68.0) 2 (33.3)
ECOG performance status
 0 42 (84.0) 5 (83.3)
 1 8 (16.0) 1 (16.7)
 2 0 (0) 0 (0)
Primary tumor
 Right 23 (46.0) 4 (66.7)
 Left 15 (30.0) 2 (33.3)
 Rectum 12 (24.0) 0 (0)
No. of involved organs
 1 13 (26.0) 4 (66.7)
 > 1 37 (74.0) 2 (33.3)
Liver metastases
 Yes 23 (46.0) 6 (100)
 No 27 (54.0) 0 (0)
Peritoneal metastases
 Yes 18 (36.0) 1 (16.7)
 No 32 (64.0) 5 (83.3)
Distant lymph node metastasis
 Yes 38 (76.0) 5 (83.3)
 No 12 (24.0) 1 (16.7)
Lung metastasis
 Yes 9 (18.0) 0 (0)
 No 41 (82.0) 6 (100)
Mucinous or signet-ring cell components
 Yes 9 (18.0) 1 (16.7)
 No 41 (42.0) 5 (83.3)
Differentiation (adenocarcinoma)a
 Well-moderate 27 (54.0) 4 (66.7)
 Poor 20 (40.0) 2 (33.3)
  1. All values are presented as number of patients followed by percentage in parentheses
  2. FOLFOXIRI 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan
  3. aThree cases were pure signet-ring cell carcinomas or mucinous carcinomas and were excluded here